Join our email list!

Get daily updates delivered to your inbox
Thank you for subscribing

Relapsing vs Progressive Multiple Sclerosis


Recently, the U.S. Food and Drug Administration (FDA) gave priority review to a request to approve Ocrevus (ocrelizumab) as a treatment for both relapsing and primary progressive MS.

But each form of the disease has its own peculiarities.

In this video from msworldinc, watch Dr. Daniel Kantor discussing with Dr. Jay Rosenberg, Dr. Jonathan Calkwood, Dr. Heidi Crayton,and Dr. Samuel Hunter the differences between relapsing and progressive forms of multiple sclerosis (MS).

Learn more about the 1st potential therapy for primary progressive MS, Ocrelizumab here.

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

One comment

  1. I just submitted some comments about my journey with PRMS, but neglected to ask my question, so I’ll do that now. My questions are,Should I be taking rebiff if I can’t ‘feel’ or detect any relapses happening?
    Is it true that the purpose of Rebiff for me is to ward off another severe attack such as I experienced 12 years ago? And is there any way for me to recover at all from the damage that was done by that severe attack?

Leave a Comment

Your email address will not be published. Required fields are marked *